A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis

Atopic Dermatitis

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Acta Derm Venereol

Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S

doi: 10.2340/actadv.v104.18452

Atopic Dermatitis

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

J Am Acad Dermatol

Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA

doi: 10.1016/j.jaad.2024.04.026

Atopic Dermatitis

Self-Guided vs Clinician-Guided Online Cognitive Behavioral Therapy for Atopic Dermatitis: A Randomized Clinical Trial

JAMA Dermatol

Kern D, Ljótsson B, Lönndahl L, Hedman-Lagerlöf E, Molander O, Liliequist B, Bradley M, Lindefors N, Kraepelien M

doi: 10.1001/jamadermatol.2024.5044

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

J Allergy Clin Immunol Pract

Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T, FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group

doi: 10.1016/j.jaip.2024.12.001

Atopic Dermatitis

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Br J Dermatol

Weidinger S, Bewley A, Hong HC, Silvestre JF, Peris K, Wollenberg A, Ivens U, Soehoel A, Steffensen LA, Tindberg AM, Simpson EL

doi: 10.1093/bjd/ljae439

Allergic Diseases

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

Contact Dermatitis

Chicharro P, Munera-Campos M, Zaragoza-Ninet V, Giménez-Arnau A, González-Pérez R, Miquel-Miquel FJ, Córdoba-Guijarro S, Sanz-Sánchez T, Ruiz-González I, Silvestre-Salvador JF, Serra-Baldrich E, Borrego L, Pastor-Nieto MA, Ortiz de Frutos FJ, Mercader-García P, Heras-Mendaza F, Fernández-Redondo V, Rodríguez-Serna M, Hervella-García M, Carrascosa JM, Gallego-Descalzo MA, García-Doval I, Sánchez-Pérez J

doi: 10.1111/cod.14672

Atopic Dermatitis

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Br J Dermatol

Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C, UK-Irish A-STAR Study Group

doi: 10.1093/bjd/ljae287

Related content

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Self-Guided vs Clinician-Guided Online Cognitive Behavioral Therapy for Atopic Dermatitis: A Randomized Clinical Trial

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register